News

Treatment with onvuzosiran (ADX-324), Adarx Pharmaceuticals’ experimental treatment for hereditary angioedema (HAE), was well tolerated and lowered kallikrein levels and the frequency of swelling attacks, according to interim data from a Phase 1/2 trial. The data were presented at the American Academy of Allergy, Asthma & Immunology annual scientific meeting,…

On-demand treatment with deucrictibant, an experimental oral small molecule in the pipeline at Pharvaris, provides rapid relief from sudden swelling due to hereditary angioedema (HAE) and, when taken daily for up to three years, can reduce the frequency of attacks over the long term. That’s according to…

For sudden attacks of hereditary angioedema (HAE), many patients prefer — and remain satisfied with — using Ekterly (sebetralstat) oral tablets from Kalvista Therapeutics over other on-demand treatment options, because they are taken by mouth and allow swelling to be treated earlier, with sustained benefits. That’s according to new…

Treatment with tranexamic acid does not appear to improve survival in people who develop angioedema after taking angiotensin-converting enzyme inhibitors (ACEIs) to lower blood pressure, a large U.S. study found. Researchers compared more than 1,000 patients who received tranexamic acid with others who did not, and found no difference…

An older woman who developed swelling in her lung tissues was diagnosed with voriconazole-associated angioedema while receiving treatment for a fungal lung infection, according to a case report. Clinicians determined that the angioedema was likely triggered by the antifungal medication voriconazole. After discontinuation of the drug and initiation of…

More than a third of adults with hereditary angioedema (HAE) were found to have substantial difficulty recognizing their own emotions in a new single-center study in France. The data showed a moderate link between difficulty identifying and managing emotions and higher scores on a measure of depression symptoms. The…

A new international guideline recommends Ekterly (sebetralstat), Kalvista Pharmaceuticals’ approved oral therapy for hereditary angioedema (HAE), as a first-line option for timely, on-demand resolution of HAE swelling attacks in children ages 12 and older. The committee behind these new pediatric guidelines stated in a study recommendation that adolescents with…

Caring for children and adults with hereditary angioedema (HAE) places heavy demands on caregivers and can significantly affect their emotional well-being, work, and personal lives, according to a multinational survey conducted in Europe and South America. “Results of this caregiver survey revealed that the caregiver role in HAE is…

For people with hereditary angioedema (HAE), regardless of a person’s racial or ethnic background, living with this chronic disease can take a toll on emotional well-being and cause difficulty engaging in day-to-day activities, a new study found. The research specifically examined non-white patients, addressing a gap in earlier studies…

Biocryst Pharmaceuticals will present new clinical trial and real-world data on its treatments for hereditary angioedema (HAE) at this year’s American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, the company announced. The data include six abstracts reporting updated findings on Orladeyo (berotralstat), an approved oral…